Liver cancer detection and its related factors among high-risk population participating in liver cancer screening program in the Huai River Basin, Anhui Province, 2013-2018
LIU Ling-li1, ZHA Zhen-qiu2, JIA Shang-chun2, LYU Yi-li2, XU Wei2, YANG Lin-sheng1, DONG Teng-fei1, LU Man-man3, CHAI Jing3, LIU Zhi-rong1,2
1. Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, Hefei, Anhui 230032, China; 2. Anhui Provincial Center for Disease Control and Prevention, Hefei, Anhui 230601, China; 3. College of Health Management, Anhui Medical University, Hefei, Anhui 230032, China
Abstract：Objective To investigate the detection rate of liver cancer and its associated factors among high-risk population participating in liver cancer screening program in the Huai River Basin, Anhui Province from 2013 to 2018. Methods A cluster sampling method was used to select permanent residents aged 35-64 years from villages of six districts (counties) in the Huai River Basin, Anhui Province from 2013 to 2018. The population at high risk for liver cancer was assessed using health factor questionnaire and testing of hepatitis B virus surface antigen (HBsAg), of which 34,957 residents with high risk for liver cancer participated in further clinical screenings for liver cancer, including abdominal B-ultrasound examination and serum alpha-fetoprotein detection. Chi-square test and logistic regression model were used to explore the factors related to the detection rate of liver cancer. Results Among 34,957 participants undergoing clinical screenings, a total of 182 cases of liver cancer were detected, with the detection rate of was 0.52%. Multivariate regression model showed that females (OR=0.435, 95%CI:0.307-0.616), the younger group ((compared with the age group of 61-64 years), the age group of 35-40 years (OR=0.135, 95%CI:0.032-0.561, the age group of 41-50 years (OR=0.618, 95%CI:0.413-0.925)), participants with overweight (OR=0.712, 95%CI:0.522-0.973) and participants with obesity (OR=0.390, 95%CI:0.207-0.735) had lower detection rates of liver cancer. Compared with participants without cirrhosis and HBsAg positive, the detection rates ofliver cancer in those with liver cirrhosis alone (OR=7.250, 95%CI:5.142-10.221), with HBsAg positivity alone (OR=14.781, 95%CI:5.199-42.026), and with both HBsAg positivity and cirrhosis (OR=59.408, 95%CI:37.620-93.814) were significantly higher. The detection rate of liver cancer was higher in participants with more than three digestive tract symptoms (OR=2.189, 95%CI:1.474-3.251) compared with those without any digestive tract symptom. Conclusion The detection rate of liver cancer among the population participating in liver cancer screening program in the Huai River Basin, Anhui Province was lower than the national level. Participants who are male, old and have normal or low weight, HBsAg positivity, liver cirrhosis and more than 3 digestive tract symptoms have a higher detection rate of liver cancer, of which the detection rate of liver cancer in participants with liver cirrhosis and HBsAg positivity is far higher than that in other participants.
刘玲丽, 查震球, 贾尚春, 吕逸丽, 徐伟, 杨林胜, 董腾飞, 卢曼曼, 柴静, 刘志荣. 2013—2018年安徽省淮河流域肝癌早诊早治项目高危人群肝癌检出率及相关因素分析[J]. 实用预防医学, 2023, 30(2): 129-133.
LIU Ling-li, ZHA Zhen-qiu, JIA Shang-chun, LYU Yi-li, XU Wei, YANG Lin-sheng, DONG Teng-fei, LU Man-man, CHAI Jing, LIU Zhi-rong. Liver cancer detection and its related factors among high-risk population participating in liver cancer screening program in the Huai River Basin, Anhui Province, 2013-2018. , 2023, 30(2): 129-133.
[1] Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence andmortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin, 2021, 71(3):209-249. [2] Zeng H, Chen W, Zheng R, et al. Changing cancer survival in China during 2003-15: a pooled analysis of 17 population-based cancer registries[J]. Lancet Glob Health, 2018, 6(5):e555-e567. [3] Zhong JH,Peng NF,You XM,et al. Tumor stage and primary treatment of hepatocellular carcinoma at a large tertiary hospital in China: a real-world study[J]. Oncotarget, 2017, 8(11):18296-18302. [4] Tsilimigras DI, Bagante F, Sahara K, et al. Prognosis after resection of barcelona clinic liver cancer (BCLC) stage 0, A, and B hepatocellular carcinoma: a comprehensive assessment of the current BCLC classification[J]. Ann Surg Oncol, 2019, 26(11):3693-3700. [5] Ji M, Liu Z, Chang ET, et al. Mass screening for liver cancer: results from a demonstration screening project in Zhongshan City, China[J]. Sci Rep, 2018, 8(1):12787. [6] 缪伟刚, 周金意, 韩仁强, 等. 2013—2017年江苏省淮河流域地区早诊早治项目肝癌筛查分析[J]. 中国肿瘤, 2021, 30(7):511-515. [7] 吴孟超, 汤钊猷, 刘彤华, 等. 原发性肝癌规范化病理诊断指南(2015年版)[J].临床肝胆病杂志, 2015, 31(6):833-839. [8] Zeng Q, Li N, Pan XF, et al.Clinical management and treatment of obesity in China[J]. Lancet Diabetes Endocrinol, 2021, 9(6):393-405. [9] 陈万青, 李霓, 曹毛毛, 等. 2013—2017年中国城市癌症早诊早治项目基线结果分析[J].中国肿瘤, 2020, 29(1):1-6. [10] 郑莉, 戴丹, 王志强. 2011—2016年安徽省淮河流域恶性肿瘤发病与死亡分析[J]. 环境卫生学杂志, 2021, 11(6):501-505,518. [11] 安澜, 曾红梅, 郑荣寿, 等. 2015年中国肝癌流行情况分析[J].中华肿瘤杂志, 2019,41(10):721-727. [12] 王悠清, 李辉章, 王乐, 等. 2013—2018年浙江省城市癌症早诊早治项目人群肝癌筛查结果及相关因素分析[J].中华预防医学杂志, 2021, 55(3):346-352. [13] 陈悦, 徐杰茹, 杨钟泽, 等. 2005—2015年全国肝癌发病趋势分析[J].实用预防医学, 2021, 28(10):1180-1184. [14] 董佩,石菊芳,邱五七,等.2015—2017年中国城市居民肿瘤防治健康素养现况及相关因素分析[J].中华预防医学杂志,2020,54(1):76-83. [15] Sohn W, Lee HW, Lee S, et al. Obesity and the risk of primary liver cancer: a systematic review and meta-analysis[J]. Clin Mol Hepatol, 2021, 27(1):157-174. [16] 陈洁,卞修亮,朱方圆,等.肝癌中医证候要素及症状分布情况研究[J].中医肿瘤学杂志,2022,4(2):47-50. [17] Huang J, Lok V, Ngai CH, et al. Disease burden, risk factors, and recent trends of liver cancer: a global country-level analysis[J]. Liver Cancer, 2021, 10(4):330-345. [18] Coskun M. Hepatocellular carcinoma in the cirrhotic liver: evaluation using computed tomography and magnetic resonance imaging[J]. Exp Clin Transplant, 2017, 15(S2):36-44. [19] 赵鹏飞, 祖红梅, 辛晓恩, 等. 肝细胞癌发病危险因素logistic回归分析[J]. 实用肝脏病杂志, 2021, 24(6):927-929. [20] Yi SW,Choi JS,Yi JJ,et al. Risk factors for hepatocellular carcinoma by age, sex, and liver disorder status: a prospective cohort study in Korea[J]. Cancer, 2018, 124(13):2748-2757. [21] Kumar M,Kumar R,Hissar SS,et al. Risk factors analysis for hepatocellular carcinoma in patients with and without cirrhosis: a case-control study of 213 hepatocellular carcinoma patients from India[J]. J Gastroen Hepatol, 2007, 22(7):1104-1111. [22] Ringelhan M, O'Connor T, Protzer U, et al. The direct and indirect roles of HBV in liver cancer: prospective markers for HCC screening and potential therapeutic targets[J]. J Pathol, 2015, 235(2):355-367. [23] Xu Y, Zhang YG, Wang X, et al. Long-term antiviral efficacy of entecavir and liver histology improvement in Chinese patients with hepatitis B virus-related cirrhosis[J]. World J Gastroenterol, 2015, 21(25):7869-7876. [24] 周晓萍, 张玲, 吴君荣. 原发性肝癌患者症状体征与血清AFP关系的探讨[J].中国临床新医学, 2018, 11(2):128-133.
2023, Vol. 30 
